Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples

C Sarai Racey,1,2 Amy Booth,1,2 Arianne Albert,2 Laurie W Smith,2,3 Mel Krajden,4 Melanie C M Murray,2,5 Hélène C F Côte,2,6 Anna Gottschlich,1,2 David M Goldfarb,6 Manish Sadarangani,7,8 Liisa A M Galea,2,9 Angela Kaida,2,10 Lori A Brotto,2,11 Gina S Ogilvie 1,2,4

ABSTRACT

Objectives  Gathering population-based data on prevalence of SARS-CoV-2 infection is vital to the public health response and planning. Current seroprevalence data in BC are limited with respect to considerations of how socioeconomic and demographic factors, such as age, sex, gender, income, identifying as a visibility minority and occupation, are related to SARS-CoV-2 antibody detection due to infection-acquired immunity. We aimed to estimate the SARS-CoV-2 seropositivity in a cohort of British Columbians, using at-home self-collected dried blood spot (DBS) samples.

Design  This cross-sectional study included online surveys that collected sociodemographic and COVID-19 vaccine receipt information, and an at-home DBS collection kit.

Setting  British Columbia (BC), Canada.

Participants  Eligible participants were aged 25–69 years and residents of BC.

Primary outcome measure  SARS-CoV-2 anti-spike IgG antibody detection in unvaccinated individuals. Adjusted incidence rate ratios (aIRR) explored factors associated with seropositivity.

Results  SARS-CoV-2 serology was performed on a total of 4048 unvaccinated participants 25–69 years of age who submitted DBS samples taken from November 2020 to June 2021. A total of 118 seropositive cases were identified, for an estimated overall seropositivity of 2.92% (95% CI 2.42% to 3.48%). Participants identifying as a visible minority had a higher seropositivity, 5.1% vs 2.9% (p<0.003), compared with non-visible minority participants. After adjustment by age and sex, identifying as a visible minority (aIRR=1.85, 95% CI 1.20 to 2.84) remained the only significant factor associated with SARS-CoV-2 antibody detection in this cohort of unvaccinated individuals.

Conclusions  SARS-CoV-2 seropositivity in the BC population due to infection-acquired immunity was low. Seropositivity indicated that among those unvaccinated, visible minority communities have been most impacted. Continued monitoring of SARS-CoV-2 serology due to both infection-acquired and vaccine-acquired immunity will be vital in public health planning and pandemic response.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ Collection of an abundance of demographic variables allowed for a thorough investigation of factors associated with COVID-19 seropositivity.

⇒ Large sample size.

⇒ Recruiting participants from pre-existing research cohorts allowed for rapid recruitment during an emergent public health crisis, producing large amounts of useful data quickly.

⇒ Sample had over-representation of participants who were female, women, from high-income households and from urbanised areas in the lower mainland of BC.

⇒ The seropositivity estimate is for self-reported unvaccinated participants only. We were unable to verify vaccination status.

INTRODUCTION

SARS-CoV-2, which causes COVID-19, was declared a pandemic on 11 March 2020 by the WHO.1 By July 2021, the virus had caused more than 187 million confirmed cases of COVID-19 and 5 million deaths worldwide, which has climbed to 306 million cases and 5.5 million deaths since the beginning of 2022.2 In Canada, 1.4 million confirmed cases and 26,000 deaths had been reported by July 2021, which grew to 2.2 million cases and 30,000 deaths by 1 Jan 2022.3 Given the virus is transmitted via aerosols and droplets produced by symptomatic and asymptomatic people,4 the true proportion of infected individuals exceeds the confirmed case counts to date.

Many current estimates of population prevalence of SARS-CoV-2 have relied on PCR testing; however, PCR testing as surrogate for seropositivity is biased due to variations in testing recommendations and variability in population testing behaviour. Testing
guidelines and availability have varied by jurisdictions and over time. In British Columbia (BC), Canada, asymptomatic testing has not been recommended, and in the earliest phase of the pandemic, PCR-based testing was limited. Therefore, past and current prevalence estimates based on PCR test positivity under-report mild and asymptomatic cases, and individuals who were not tested while sick.

Seroepidemiological studies can provide more accurate information on the proportion of a population that has been infected with SARS-CoV-2 and has developed antibodies to the virus. Multiple studies report that more than 90% of individuals infected with SARS-CoV-2 will develop an antibody response, which is usually detectable approximately 14–28 days post infection, and has been shown to last as long as 10 months. Higher population levels of antibodies from both infection-acquired and/or vaccine-acquired immunity, may correlate with protection from subsequent SARS-CoV-2 infection.

A Canada-wide estimate of SARS-CoV-2 prevalence was released by Statistics Canada in July 2021, and based on approximately 11,000 dried blood spot (DBS) samples, found 2.6% of the population had antibodies due to infection-acquired immunity. Similar seroprevalence has been estimated from Canadian blood service donors; however, these estimates are limited with respect to socio-demographic data. Given the current seroprevalence data and the dynamic nature of both the pandemic and the public health control measures, there is an ongoing need for surveillance of SARS-CoV-2 antibodies in the general population. To date, seroprevalence data in BC are also limited with respect to considerations for how socioeconomic and demographic factors, such as age, sex, gender, education, income, location and occupation, are related to SARS-CoV-2 antibody detection due to infection-acquired immunity. Therefore, accurate estimates of SARS-CoV-2 seropositivity can help inform policy-makers on evolving pandemic responses.

The objective of this study was to estimate SARS-CoV-2 antibody prevalence due to infection-acquired immunity, using self-collected DBS, in a population-based cohort in BC, and socioeconomic and demographic factors associated with SARS-CoV-2 antibody detection.

METHODS

The Rapid Evidence Study of a Provincial Population Based COhort for GeNder and SEx (RESPONSE) was an investigation lead by the Women’s Health Research Institute of Vancouver, BC, evaluating the impact of the COVID-19 pandemic in BC, Canada.

Patient involvement

Patient partners from the existing research cohorts were consulted during the conceptualisation of the study. Patient partners were involved in the survey pilot testing. Peer research associates from specific patient groups helped administer the survey to participants who were unable to complete the survey on their own. Regular research updates have been communicated to patient groups.

Study design and recruitment

The study, described previously, included an invitation to participate in an online survey and the opportunity to provide an at-home self-collected DBS sample via a finger prick, for SARS-CoV-2 antibody testing. Recruitment for the online survey was from 20 August 2020 to 4 August 2021, with collection of DBS samples from November 2020 to June 2021.

Participants were recruited from existing large research cohorts in BC, comprised of individuals who had provided consent to be contacted for future research, in addition to general public recruitment through social media, patient research networks, as well as stakeholder and community websites (index participants). Eligible participants were those 25–69 years of age who were current residents of BC. To increase representation of diverse sex and gender participants, respondents were able to identify another adult household member of a different gender to participate (household participants). All participants from pre-existing research cohorts were sent an initial email invitation with up to three reminders, and an opportunity to enter a draw for a gift card. Participants were stratified into nine 5-year age strata with a targeted recruitment of 750 per stratum, based on an estimated population seroprevalence of 2% (±1, 95% CI).

Survey design

The survey comprised multiple modules all based on self-reported information, which have been analysed separately. Demographic information was collected for age, sex, gender, indigenous ancestry, visible minority status (identifying as non-white), education, income, household composition, employment as a healthcare worker (HCW), other essential worker, or an non-essential worker, geographic region of residence assigned to one of the five provincial health authorities (assessed via the first three digits of postal code). Health information on existing chronic disease conditions and self-reported history of COVID-19 was also collected. The survey was tested for face validity and pilot tested. At the completion of the survey, participants could opt-in to receive the at-home self-collected DBS kit.

COVID-19 vaccination status was self-reported through a second survey specific to vaccine status, which was sent to all participants who submitted a DBS sample, on receipt of their DBS sample at the processing lab. COVID-19 vaccine information collected included date of first dose and vaccine product information. All surveys were distributed using the Research Electronic Data Capture (REDCap) online platform.

Serology

All survey participants who opted-in for SARS-CoV-2 antibody testing were mailed an at-home DBS self-collection
kit. The at-home self-collection kit was compiled by the research team using commercially available products, which included a protein saver card with five blood spot collection circles, lancets, alcohol swab, gauze, and pictorial and descriptive instructions (online supplemental material). Participants were asked to record the date of sample collection and to mail their sample within 12 hours of collection using a prepaid envelope to the BC Center for Disease Control Provincial Laboratory, which performed all SARS-CoV-2 antibody research serology testing.\textsuperscript{17}

Following best practices at the time of study completion, SARS-CoV-2 antibody testing was measured by DBS using Meso Scale Discovery’s (MSD) quantitative multiplex anti-immunoglobulin G (IgG) electrochemiluminescence assay (V-PLEX COVID-19 Coronavirus Panel 2 (IgG) Kit). The MSD assay was validated for research purposes for SARS-CoV-2 anti-spike (S) immunoglobulin G (IgG) reactivity,\textsuperscript{17} which achieved a sensitivity of 79% and specificity of 97% compared to paired serum samples in an unvaccinated population. MSD assay was not approved by health agencies for diagnostic testing at the time of the study. Participants were categorised as SARS-CoV-2 serology positive based on the anti-S result, with a positive threshold cut-off defined as S≥75 AU/mL.\textsuperscript{17}

### Statistical analysis

SARS-CoV-2 seropositivity was estimated in a cohort that reported being unvaccinated at the time of DBS self-collection (figure 1). Those who self-reported as receiving a COVID-19 vaccine prior to DBS collection, as well as those with unknown vaccination status, were excluded from the seroprevalence estimate. Sensitivity analysis was also done, which included those with unknown vaccination status as unvaccinated.

Generalised estimating equations with a Poisson link were used to estimate the bivariable and multivariable incidence rate ratios (IRR), controlling for clustering due to index and household participants. Multivariable adjustment was based on bivariate analysis (p<0.10) associated with SARS-CoV-19 infection, in addition to a priori variables associated with SARS-CoV-2 infection: age, sex, being an essential worker and identifying as a visible minority. All analyses were performed in R v. 4.0.2.\textsuperscript{18}

### RESULTS

#### Participant characteristics

Between 20 August 2020 and 4 August 2021, a total of 5470 participants completed the online survey and requested a DBS at-home collection kit. A total of 5402 DBS at-home collection kits were mailed to participants, of which

---

**Figure 1** Participants included in this seroprevalence analysis based on recruitment. Categorisation of participants based on self-reported COVID-19 vaccination status (at least 1 dose) and SARS-CoV-2 antibody testing in British Columbia, Canada, on at-home dried blood spot (DBS) samples from November 2020 to June 2021. *Ineligible denotes participants who did not submit the survey, which was required to be able to prompt the request for a DBS testing kit. Note: Participants were categorised as SARS-CoV-2 antibody positive based on the anti-Spike (anti-S) result, with a positive threshold cut-off defined as anti-S >75 AU/mL.\textsuperscript{17}
4422 participants submitted a DBS sample for analysis, which included 3981 (90.0%) index participants and 441 (10.0%) household participants (figure 1). There were 234 (5.3%) vaccinated participants and 140 participants with an unknown vaccine status that were removed from analysis, resulting in a total of 4048 participants included in this main analysis. The DBS collection period for those included in the analysis was from November 2020 to June 2021.

The majority of participants identified as female (88.0%), and 87.2% identified as women, with 1% of participants identifying as gender diverse. Overall, 13.0% identified as a visible minority, and HCWs comprised 11.2% of participants (table 1).

DBS self-collection took place between 10 November 2020 and 6 July 2021, during the second wave of the pandemic, with the last DBS sample included in this analysis collected on 2 June 2021 (figure 2). The daily new infection incidence rate in BC during the same time frame ranged from 5 per 100000 at the beginning of wave 2 to more than 20 per 100000 at the peak of wave 3 (figure 2).

A total of 118 positive cases were reported for a seropositivity estimate of 2.92% (95% CI 2.42% to 3.48%). There was a significant association between ethnicity and seropositivity, with those identifying as a visible minority having a seropositivity of 5.1% vs 2.6% (p=0.003) among non-visible minority participants. Participants were also asked if they thought they had COVID-19 at any point since the start of the pandemic and survey completion. There was a significantly higher seropositivity in those who reported thinking that they had COVID-19 (7.7% vs 2.1%). There were 16 participants who reported receiving a positive COVID-19 test result, of which 15/16 (93.8%) were also seropositive. The one participant who was seronegative reported a positive COVID-19 test result from August 2020 and completed DBS collection January 2021.

There was a delay in the distribution of DBS collection kits, relative to demographic survey completion; as a result, those who completed the survey earlier had a longer lag time between survey completion and DBS collection. The mean time lag between survey completion and DBS collection was 112 days (SD=35), and there was no difference in lag time between those that tested positive (mean=109 days) or negative (mean=112 days) (p=0.5). The secondary vaccination status survey was automatically sent to a participant when their DBS sample arrived at the laboratory for processing.

**Bivariable and multivariable associations with SARS-CoV-2 seropositivity**

In bivariable analysis, identifying as a visible minority (IRR 1.98, 95% CI 1.30 to 3.01), an HCW (IRR 1.63, 95% CI 1.01 to 2.64) and thinking you had COVID-19 (IRR 3.6, 95% CI 2.48 to 5.22) were significantly associated with seropositivity (table 2). Age, sex, gender, level of education, income, number of adults living in the household, having a chronic health condition and geographical location of residents (based on health authority) were not significantly different between those who were positive or negative on serology (table 2).

The multivariable adjusted for age and sex, however, only identifying as a visible minority (adjusted IRR (aIRR)=1.85, 95% CI 1.20 to 2.84) remained significantly associated with seropositivity, while being an HCW did not (aIRR=1.49, 95% CI 0.92 to 2.43) (table 2).

**Sensitivity analysis with unknown vaccine status**

In a sensitivity analysis, the 140 participants excluded from the main analysis due to unknown vaccination status were included as unvaccinated. Of the 140 excluded, 13 had antibodies detected. There was no significant change in the factors associated with seropositivity, apart from essential HCWs, where the effect size increased from aIRR=1.49 (95% CI 0.92 to 2.43) to aIRR=1.89 (95% CI 1.23 to 2.91).

**DISCUSSION**

In this BC cohort of adults from the general population, the SARS-CoV-2 seropositivity was estimated to be 2.92% (95% CI 2.42% to 3.48%) among unvaccinated individuals for samples collected between November 2020 and June 2021, measuring seropositivity throughout the second wave of the pandemic in BC (figure 2).

A Canadian-wide StatsCan estimate reported that 3.6% of Canadians had antibodies to SARS-CoV-2, with 2.6% having antibodies due to infection-acquired immunity, and 1% due to vaccine-acquired immunity, during a similar time frame from November 2020 to April 2021, which is an increase compared with Canadian seroprevalence estimates of 0.7%–1.7% from May to July 2020 (first wave). However, seroprevalence estimates from after the second wave have varied by location. The StatsCan report found that after the second wave, Alberta had the highest seroprevalence at 4.0%, followed by central Canada, ranging from 2.5% to 2.9%, with BC estimated at 1.6% and Atlantic Canada estimated at 0.5%. A second study estimated seroprevalence after the second wave to be as high as 7.0% in the Prairie provinces, 6.4% in BC and as low as 3.3% in the Atlantic provinces. Our study cohort seropositivity as measured throughout the second wave was 2.92%, which was between the afore-mentioned population estimates of 1.6% (StatsCan) and 6.4% for seroprevalence in BC after the second wave.

Globally, geographic estimates of SARS-CoV-2 seropositivity in populations are extremely varied, depending on location, population size, testing guidelines and access, and dynamics of the pandemic. In a meta-analysis of 241 studies, the global pooled SARS-CoV-2 antibody prevalence was 9.5%, and ranged from 1.6% in South-eastern Asia and 22.9% in Southern Asia. In countries with a similar socioeconomic profile as Canada, the estimated seroprevalence has varied widely, with 0.1% seroprevalence in New Zealand at the end of 2020, 5.6% in England in October–November 2020, 20.2% in the USA from July to
|                                      | Total N=4048 | Serology result (IgG anti-Spike) | P value* |
|--------------------------------------|--------------|----------------------------------|----------|
|                                      |              | **Negative n=3930**              | **Positive n=118** |
| Mean age (SD)                        | 49.9 (±11.8) | 49.9 (±11.7)                     | 48.4 (±13.0) | 0.21 |
| Age                                  |              |                                  |           |
| 25–29                                | 223 (5.5%)   | 213 (95.5%)                      | 10 (4.5%)  | 0.05 |
| 30–39                                | 693 (17.1%)  | 668 (96.4%)                      | 25 (3.6%)  |       |
| 40–49                                | 961 (23.7%)  | 930 (96.8%)                      | 31 (3.2%)  |       |
| 50–59                                | 1116 (27.6%) | 1096 (98.2%)                     | 20 (1.8%)  |       |
| 60–70                                | 1055 (26.1%) | 1023 (97.0%)                     | 32 (3.0%)  |       |
| Sex                                  |              |                                  |           |
| Female                               | 3563 (88.0%) | 3460 (97.1%)                     | 103 (2.9%) | 1     |
| Male                                 | 480 (11.9%)  | 466 (97.1%)                      | 14 (2.9%)  |       |
| Missing                              | 5 (0.1%)     | 4 (80.0%)                        | 1 (20.0%)  |       |
| Gender                               |              |                                  |           |
| Woman                                | 3528 (87.2%) | 3425 (97.1%)                     | 103 (2.9%) | 1     |
| Man                                  | 478 (11.8%)  | 464 (97.1%)                      | 14 (2.9%)  |       |
| Gender diverse                       | 42 (1.0%)    | 41 (97.6%)                       | 1 (2.4%)   |       |
| Indigenous identity                  |              |                                  |           |
| Indigenous                           | 93 (2.3%)    | 89 (95.7%)                       | 4 (4.3%)   | 0.55 |
| Not indigenous                       | 3771 (93.2%) | 3658 (97.0%)                     | 113 (3.0%) |       |
| Prefer not to answer                 | 27 (0.7%)    | 27 (100.0%)                      | 0 (0.0%)   |       |
| Missing                              | 157 (3.9%)   | 156 (99.4%)                      | 1 (0.6%)   |       |
| Visible minority                     |              |                                  |           |
| Visible minority                     | 527 (13.0%)  | 500 (94.9%)                      | 27 (5.1%)  | 0.003 |
| Non-visible minority                 | 3502 (86.5%) | 3411 (97.4%)                     | 91 (2.6%)  |       |
| Missing                              | 19 (0.5%)    | 19 (100.0%)                      | 0 (0.0%)   |       |
| Visible minorities                   |              |                                  |           |
| White                                | 3460 (85.5%) | 3369 (97.4%)                     | 91 (2.6%)  | 0.048 |
| Black                                | 17 (0.4%)    | 17 (100.0%)                      | 0 (0.0%)   |       |
| East Asian                           | 271 (6.7%)   | 257 (94.8%)                      | 14 (5.2%)  |       |
| Hispanic/Latinx                      | 49 (1.2%)    | 48 (98.0%)                       | 1 (2.0%)   |       |
| Other                                | 167 (4.1%)   | 161 (96.4%)                      | 6 (3.6%)   |       |
| South Asian                          | 61 (1.5%)    | 56 (91.8%)                       | 5 (8.2%)   |       |
| Southeast Asian                      | 23 (0.6%)    | 22 (95.7%)                       | 1 (4.3%)   |       |
| Education                            |              |                                  |           |
| More than high school                | 3530 (87.2%) | 3425 (97.0%)                     | 105 (3.0%) | 0.67 |
| High school or less                  | 509 (12.6%)  | 496 (97.4%)                      | 13 (2.6%)  |       |
| Missing                              | 9 (0.2%)     | 9 (100.0%)                       | 0 (0.0%)   |       |
| Household income                     |              |                                  |           |
| US$100k+                             | 2048 (50.6%) | 1991 (97.2%)                     | 57 (2.8%)  | 0.51 |
| ≤US$49k                              | 427 (10.5%)  | 411 (96.3%)                      | 16 (3.7%)  |       |
| US$50k–US$100k                       | 1048 (25.9%) | 1019 (97.2%)                     | 29 (2.8%)  |       |
| Missing                              | 525 (13.0%)  | 509 (97.0%)                      | 16 (3.0%)  |       |

Occupation group†

Continued
The factors significantly associated with seropositivity in this cohort included identifying as a visible minority and working as an essential health care worker. Both of these factors have been identified in other jurisdictions as being highly associated with COVID-19.29–31 Participants identifying as a visible minority had a higher seropositivity (5.1%) compared with non-visible minorities (2.6%). In this cohort, the visible minority groups of East Asian, South Asian and Southeast Asian represented 67.4% of participants who identified as a visible minority. Identifying as a visible minority had the largest effect size for having SARS-CoV-2 antibodies, even after adjustment for other key demographic factors associated with COVID-19 infection. The elevated risk and overall higher proportion of SARS-CoV-2 infection among visible minority Canadians has been identified across the country.12 32

Within the same RESPPONSE cohort, future COVID-19 vaccine intention was lower among those who identified as a visible minority.13 Our findings suggest there is a need to identify strategies to...
mitigate both infection risk and support communities for immunisation.

Those working as HCWs had an IRR of 1.63 (95% CI 1.01 to 2.64), indicating an elevated risk for being seropositive compared with non-essential workers; however, after adjusting for age, sex and being a visible minority, the increased risk was no longer significant. Increased risk in HCWs has been previously observed in data from other jurisdictions.\(^29\)\(^30\) We estimated the seroprevalence in unvaccinated HCWs to be 4.4%, which is lower than previous national estimates by the national COVID-19 surveillance system, which reported the seropositive cases by occupation in a healthcare setting, and found the prevalence in HCWs has been declining over time from May to September 2020, with estimate of 6.5% from 1 September to 14 September 2020.\(^33\)

The elevated seropositivity in HCWs, compared with non-essential workers, is an important finding, but one that should be interpreted with caution. The exclusion of those who had received the vaccine prior to obtaining a blood sample likely resulted in the exclusion of HCWs based on the COVID-19 vaccine programme rollout in BC at the time of the study, for which priority eligibility was given to HCWs. In the sensitivity analysis of the 140 participants with unknown vaccination status, they were included as unvaccinated. The overall findings were very similar, except for an increase in the seropositivity among HCWs, which increased from 4.4% (vs 2.7%, p=0.14) to 5.7% (vs 2.8%, p=0.006); however, it is unknown if antibody detection was due to infection-acquired or vaccine-acquired immunity. We felt the elevated seropositivity in the sensitivity analysis was likely due in large part to

---

**Figure 2** Rapid Evidence Study of a Provincial Population Based COhort for GeNder and Sex (RESSPONSE) dried blood spot (DBS) collection relative to recorded daily case counts per 100,000 and test positivity in British Columbia (BC) (March 2020 to December 2021). Top: DBS collection period from November 2020 to June 2021, and % of DBS samples collected per month of the study period (n=4048). Bottom: Epidemiological curve of cases per 100k population for BC March 2020 to December 2021 as per left-hand y-axis. Test positivity is indicated with colour scale, with daily test rate (PCR tests) per 1k population in the shaded area as per the right-hand y-axis (Adapted from BCCDC Dec 2021).
misclassification of HCWs’ vaccination status as opposed to infection-acquired immunity, again based on the vaccine programme’s priority eligibility of HCWs at the time of the study. Given the overall findings from the sensitivity analysis were similar, participants with unknown vaccine status were excluded from the main analysis. Overall, our findings indicate that among unvaccinated HCWs at the time of sample collection, the seropositivity was higher compared with non-essential workers and other essential workers.

We did not find a significant association between being positive for SARS-CoV-2 antibodies and other participant

Table 2  Bivariable and multivariable analysis of research serology for SARS-CoV-2 antibodies in a population cohort in British Columbia, Canada, with at-home dried blood spot samples from November 2020 to June 2021

| Predictors                           | Unadjusted | Adjusted* |
|--------------------------------------|------------|-----------|
|                                      | IRR        | 95% CI    | P value | IRR        | 95% CI    | P value |
| Age                                  | 0.99       | 0.97 to 1.01 | 0.206  | 0.99       | 0.98 to 1.01 | 0.488  |
| Sex                                  |            |           |         |            |           |         |
| Female                               | Reference  |           |         | Reference  |           |         |
| Male                                 | 1.01       | 0.59 to 1.73 | 0.976  | 1.04       | 0.60 to 1.79 | 0.89   |
| Occupation                           |            |           |         |            |           |         |
| Non-essential worker                 | Reference  |           |         | Reference  |           |         |
| Essential worker—healthcare Worker   | 1.63       | 1.01 to 2.64 | 0.047  | 1.49       | 0.92 to 2.43 | 0.109  |
| Essential worker—other essential worker | 1.03       | 0.63 to 1.68 | 0.902  | 1         | 0.61 to 1.63 | 0.984  |
| Visible minority                     |            |           |         |            |           |         |
| Non-visible minority                 | Reference  |           |         | Reference  |           |         |
| Visible minority                     | 1.98       | 1.30 to 3.01 | 0.001  | 1.85       | 1.20 to 2.84 | 0.005  |
| Income                               |            |           |         |            |           |         |
| US$100k+                             | Reference  |           |         | Reference  |           |         |
| US$50k–US$100k                       | 0.99       | 0.64 to 1.55 | 0.98   |            |           |         |
| ≤US$49k                              | 1.35       | 0.78 to 2.33 | 0.288  |            |           |         |
| Education                            |            |           |         |            |           |         |
| More than high school                | Reference  |           |         | Reference  |           |         |
| High school or less                  | 0.86       | 0.49 to 1.52 | 0.601  |            |           |         |
| Geographical location                |            |           |         |            |           |         |
| Region 1                             | Reference  |           |         | Reference  |           |         |
| Region 2                             | 0.71       | 0.22 to 2.29 | 0.569  |            |           |         |
| Region 3                             | 0.85       | 0.12 to 6.09 | 0.873  |            |           |         |
| Region 4                             | 1.11       | 0.70 to 1.74 | 0.665  |            |           |         |
| Region 5                             | 0.6        | 0.31 to 1.15 | 0.122  |            |           |         |
| Health status                        |            |           |         |            |           |         |
| No chronic health conditions         | Reference  |           |         | Reference  |           |         |
| One or more chronic health conditions | 1.11       | 0.78 to 1.59 | 0.559  |            |           |         |
| Number of adults in the household    |            |           |         |            |           |         |
| One adult                            | Reference  |           |         | Reference  |           |         |
| Two adults                           | 1.09       | 0.69 to 1.70 | 0.717  |            |           |         |
| Three or more adults                 | 1.15       | 0.67 to 1.97 | 0.623  |            |           |         |
| Think they had COVID-19              |            |           |         |            |           |         |
| No                                   | Reference  |           |         | Reference  |           |         |
| Yes                                  | 3.6        | 2.48 to 5.22 | <0.001 |            |           |         |

Bolded values in the Table indicate a significance of >0.05.

*n= 4018; adjusted model included age, sex, occupation and visible minority.
characteristics, namely age, sex, gender, level of education, income, number of adults living in the household, having a chronic disease or geographical location of residence based on provincial health authority. Recent population-based seroprevalence studies have had similar findings, although small associations with increased seroprevalence have been observed in younger adults and those living in multifamily dwellings.31 34 35 In our cohort, younger adults (25–29 years) had higher seroprevalence (4.5%) compared with the other age groups; however, the difference was not significant. We did not see a significant association between seroprevalence and sex (with 2.9% of males and 2.9% of females being seropositive), which may have been due to the sample being 88% female; however, other Canadian seroprevalence data likewise has not found a significant association between infection-acquire immunity and reported sex.11

We did not observe an association between seropositivity and household density, as measured by the number of adults in the household, where 20% of participants in our study reported living in households of three or more adults. In a large meta-analysis exploring household transmission, findings indicated that households were an important source of transmission; however, transmission was associated more with the types of relationships within the household, rather than number of adults in the household.36

In our cohort, over half the study population reported having one or more chronic diseases; however, we did not find an association between having a chronic disease and SARS-CoV-2 serology status. Chronic disease comorbidities have been associated with increased disease severity with COVID-19; however, the evidence is limited for chronic disease comorbidity as risk factor for infection itself.34 38 The lack of association between chronic diseases and SARS-CoV-2 antibodies in our study may be due to the public health messaging around the risk for severe disease associated with chronic diseases, where individuals may have made efforts to limit their exposure through increased precaution measures. This may have included participants working from home, given that 70% of the cohort reported as non-essential workers.

Limitations
This study has limitations. First, RESPONSE study participants were primarily recruited from pre-existing general population research cohorts, which yielded a sample with over-representation of females, women, and high-income households, in addition to participants residing in predominately urbanised areas in the lower mainland of BC, compared with the provincial population of BC. Second, there was the potential for response bias, in that those who were concerned about COVID-19, or wished to access serology testing, may have been more likely to participate regardless of their actual risk to having acquired COVID-19, which may further limit the generalisability of our findings. Third, our seropositivity estimate is only among unvaccinated participants based on self-reported vaccination status based on the vaccine status survey, which was electronically sent to them when their DBS sample was received at the lab. Those with self-reported vaccination and those with unknown vaccination status (incomplete vaccine status survey) were removed from the main analysis to limit the potential for misclassification, due to the inability to discern between infection-acquired or vaccine-acquired immunity. Those who self-reported vaccination prior to DBS collection date were assigned as vaccinated, regardless of the time between vaccination and DBS collection, which may further bias our findings to the null, given those who were vaccinated within close proximity prior to their DBS collection were classified as vaccinated, even though vaccine-acquired antibodies may not have been detectable.

We must also acknowledge the limitation of DBS for serology testing compared with other whole blood serum samples. However, DBS has a number of advantages to consider, including self-collection, transportation, and storage when conducting population and surveillance serological studies.17

CONCLUSION
SARS-CoV-2 antibody seropositivity due to infection-acquired immunity remained low in BC during the second wave of the pandemic. Seropositivity indicated that among those unvaccinated, visible minority communities have been disproportionately impacted. Continued monitoring of SARS-CoV-2 serology due to both infection-acquired and vaccine-acquired immunity will be vital in public health planning and ongoing pandemic response.

Author affiliations
1School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada
2British Columbia Women’s Hospital and Health Centre, Women’s Health Research Institute, Vancouver, British Columbia, Canada
3Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada
4BC Centre for Disease Control, Vancouver, British Columbia, Canada
5Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada
6Pathology and Laboratory Medicine, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada
7Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada
8Vaccine Evaluation Center, BC Children’s Hospital Research Institute, Vancouver, British Columbia, Canada
9Department of Psychology, The University of British Columbia, Vancouver, British Columbia, Canada
10Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada
11Department of Obstetrics & Gynaecology, The University of British Columbia, Vancouver, British Columbia, Canada

Twitter Melanie C M Murray @DrMelanieMurray

Contributors All authors contributed significantly to the study. All authors received and approved this manuscript. CSR: Methodology, formal analysis, manuscript drafting. AB: Project administration, data collection, formal analysis, manuscript drafting. AA: Study conceptualisation, methodology, formal analysis. LWS: Study conceptualisation, project administration, data collection. MK: Methodology,
data collection. MCMM: Study conceptualisation, methodology. HCFC: study conceptualisation, methodology. AG: Methodology. DMG: Study conceptualisation, methodology. MS: Study conceptualisation, methodology. LAMG: Study conceptualisation, methodology, project administration. AK: Study conceptualisation, methodology, project administration. LAB: Study conceptualisation, methodology, project administration, data collection. GSO: Guarantor, Study conceptualisation, methodology, project administration, data collection, formal analysis, manuscript drafting.

Funding The Rapid Evidence Study of a Provincial Population Based Cohort for GeNoDer and SEx (RESPONSE) study was supported by the BC Women’s Hospital Foundation grant #LRZ30421 and a Michael Smith Foundation for Health Research grant # COV-2021-2263.

Competing interests MS has been a investigator on projects funded by GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. MCM has been an investigator on a non-vaccine related project funded by GSKxiv, and has received honoraria for non-vaccine related activities both personally and paid to her institution from Merck, and Gilead Sciences. MK has received contracts paid to his institution from Roche, Siemens and Gilead and unrelated to this work. Other authors have no declarations.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the University of British Columbia Research Ethics Board #H20-01421. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. The data collected from the online survey is not available. At the time of consent participants were not advised that data might be made publicly available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Laurie W Smith http://orcid.org/0000-0002-9463-1713
Gina S Ogilvie http://orcid.org/0000-0001-5783-4493

REFERENCES
1 WHO. Timeline: WHO’s COVID-19 response [Internet]. WHO, 2020. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline [Accessed cited 2021 Sep 29].
2 WHO. WHO. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2020. Available: https://covid19.who.int [Accessed cited 2021 Sep 29].
3 Government of Canada. COVID-19 daily epidemiology update [Internet]. 2021. Available: https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html [Accessed cited 2021 Sep 29].
4 Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323:1406–7.
5 BCCDC. When to get a COVID-19 test [Internet]. BCCDC, 2021. Available: http://www.bccdc.ca/health-info/diseases-conditions/covid-19/testing/when-to-get-a-covid-19-test
6 Lau EYH, Tsang OTY, Hui DSC, EHY L, DSC H, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 2021;12:1–7.
7 Wang H, Yuan Y, Xiao M, et al. Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection. Cell Mol Immunol 2021;18:1832–4.
8 Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunity 2020;52:737–41.
9 Khoury DS, Cromer D, Reynolds A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205–11.
10 Jeffery-Smith A, Rowland TAJ, Patel M, et al. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. Lancet Healthy Longev 2021;2:811–9.
11 Statistics Canada. Table 13-10-0818-01 SARS-CoV-2 antibody serorepervence in Canadians, by age group and sex, November 2020 to April 2021 [Internet], 2021. Available: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=131081801
12 COVID-19 Immunity Task Force. Latest Canadian Blood Services data show improvements in vaccine uptake and equity in vaccine coverage [Internet], 2021. Available: https://www.covid19immunitytaskforce.ca/latest-canadian-blood-services-data-show-improvements-in-vaccine-uptake-and-equity-in-vaccine-coverage/
13 Ogilvie GS, Gordon S, Smith LW, et al. Intention to receive a COVID-19 vaccine: results from a population-based survey in Canada. BMC Public Health 2021;21:1–14.
14 Kaida A, Brocto LA, Murray MCM, et al. Intention to receive a COVID-19 vaccine by HIV status among a population-based sample of women and gender diverse individuals in British Columbia, Canada. AIDS Behav 2022;26:2242.
15 Brocto LA, Chanksasingh K, Baaske A, et al. The influence of sex, gender, age, and ethnicity on psychosocial factors and substance use throughout phases of the COVID-19 pandemic. PLoS One 2021;16:e0293676–22.
16 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research Informatics support. J Biomed Inform 2009;42:377–81 https://linkinghub.elsevier.com/retrieve/pii/S1532046408001226.
17 Nikiforuk AM, McMillan B, Bartlett SR, et al. Performance of immunglobulin G serology on finger prick capillary dried blood spot samples to detect a SARS-CoV-2 antibody response. Microbiol Spectr 2022;10:1–10.
18 R Core Team. The R project for statistical computing: v4.0.2, 2020.
19 Canadian Blood Services. COVID-19 Seroprevalence Report - August 19, 2020 [Internet], 2020. Available: https://www.blood.ca/sites/default/files/CBS_COVID_19_Seroprevalence_Public_Report_Aug272020.pdf.
20 Tang X, Sharma A, Pasic M, et al. COVID symptoms, seroprevalence, and mortality during the first wave of SARS-CoV-2 in Canada. SSRN, 2021.
21 Tang X, Sharma A, Pasic M, et al. SARS-CoV-2 Seroprevalence During the First and Second Pandemic Waves in Canada. SSRN [Internet], 2021. Available: https://ssrn.com/abstract=3900344.
22 Rostami A, Sepidarkish M, Fazlzaadeh A, et al. Update on SARS-CoV-2 seroprevalence: regional and worldwide. Clin Microbiol Infect 2021;27:1762–71.
23 Rostami A, Sepidarkish M, Leealleng MMG, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect 2021;27:331–40.
24 Malani A, Shah D, Kang G, et al. Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. Lancet Glob Health 2021;9:e110–1.
25 Carlton LH, Chen T, Whitcombe AL, et al. Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand. Epidemiol Infect 2021;149:e173.
26 Ward H, Atchison C, Whitter M, et al. Increasing SARS-CoV-2 antibody prevalence in England at the start of the second wave. REACT-2 round 4 cross-sectional study in 160,000 adults. medRxiv 2021:1–13.
27 Jones JM, Stone M, Sulaiman H, et al. Estimated Us Infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020–May 2021. JAMA 2021;326:1400–10.
28 Leclercq V, Van den Houte N, Gisle L, et al. Prevalence of Anti-SARS-CoV-2 antibodies and potential determinants among the Belgian adult population: baseline results of a prospective cohort study. Viruses 2022;14: doi:10.3390/v14050920. [Epub ahead of print: 28 04 2022].
29 Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among frontline health-care workers and the general community:
a prospective cohort study. *Lancet Public Health* 2020;5:e475–83.

30 Shah ASV, Wood R, Gribben C, et al. Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. *BMJ* 2020;371. doi:10.1136/bmj.m3582. [Epub ahead of print: Available from] https://www.bmj.com/content/371/bmj.m3582

31 BobrovitzN, AroraRK, Caoc. Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis. *PLoS One* 2021;16:21.

32 Statistics Canada. Few Canadians had antibodies against SARS-CoV-2 in early 2021 [Internet], 2021. Available: https://www150.statcan.gc.ca/n1/daily-quotidien/210706/dq210706a-eng.htm

33 Public Health Agency of Canada. COVID-19 infections among healthcare workers and other people working in healthcare settings [Internet], 2021. Available: https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/epidemiological-economic-research-data/infections-healthcare-workers-other-people-working-healthcare-settings.html

34 Rogawski McQuade ET, Guertin KA, Becker L, et al. Assessment of seroprevalence of SARS-CoV-2 and risk factors associated with COVID-19 infection among outpatients in Virginia. *JAMA Netw Open* 2021;4:e2035234.

35 Chen X, Chen Z, Azman AS, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. *Lancet Glob Health* 2021;9:e598–609.

36 Madewell ZJ, Yang Y, Longini IM, et al. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. *JAMA Netw Open* 2020;3:e2031756.

37 Li X, Zhong X, Wang Y, et al. Clinical determinants of the severity of COVID-19: a systematic review and meta-analysis. *PLoS One* 2021;16:e0250602–21.

38 Lai C-C, Wang J-H, Hsueh P-R. Population-Based seroprevalence surveys of anti-SARS-CoV-2 antibody: an up-to-date review. *Int J Infect Dis* 2020;101:314–22.